Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials

Background: Immune checkpoint inhibitors (ICIs) have been a significant milestone for the treatment of advanced non-small cell lung cancer (NSCLC). However, the efficacy of ICIs can vary substantially between patients, with disparities in treatment outcomes being potentially driving by changes in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Manning-Bennett, Arkady T, Cervesi, Julie, Bandinelli, Pierre-Alain, Sorich, Michael J, Hopkins, Ashley M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953420/
https://www.ncbi.nlm.nih.gov/pubmed/36831064
http://dx.doi.org/10.3390/biomedicines11020528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953420/
https://www.ncbi.nlm.nih.gov/pubmed/36831064
http://dx.doi.org/10.3390/biomedicines11020528

Ejemplares similares